Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigator-initiated Expanded access program for cannabidivarin in seizures associated with autism

Trial Profile

Investigator-initiated Expanded access program for cannabidivarin in seizures associated with autism

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Autistic disorder; Seizures
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2018 According to a GW Pharmaceuticals media release, initial data (n=5) will be presented at the American Epilepsy Society.
    • 21 Feb 2018 According to a GW Pharmaceuticals media release, Open label data from the expanded access IND are expected later in 2018
    • 05 Feb 2018 Status changed from planning to recruiting, according to a a GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top